H
Hossein Rahimi
Researcher at Mashhad University of Medical Sciences
Publications - 38
Citations - 377
Hossein Rahimi is an academic researcher from Mashhad University of Medical Sciences. The author has contributed to research in topics: Medicine & Adult T-cell leukemia/lymphoma. The author has an hindex of 6, co-authored 32 publications receiving 292 citations.
Papers
More filters
Journal ArticleDOI
Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia-lymphoma (ATL)
Ghada Kchour,Mahdi Tarhini,Mohamad Mehdi Kooshyar,Hiba El Hajj,Eric Wattel,Mahmoud Mahmoudi,Hassan A. Hatoum,Hossein Rahimi,Masoud Maleki,Houshang Rafatpanah,S.A. Rahim Rezaee,Mojtaba Tabatabaei Yazdi,Abbas Shirdel,Olivier Hermine,Reza Farid,Ali Bazarbachi +15 more
TL;DR: Treatment of chronic ATL with arsenic, interferon-alpha, and zidovudine is feasible and exhibits an impressive response rate with moderate toxicity, which strengthens the concept of oncogene-targeted cancer therapy.
Journal ArticleDOI
The combination of arsenic, interferon-alpha, and zidovudine restores an “immunocompetent-like” cytokine expression profile in patients with adult T-cell leukemia lymphoma
Ghada Kchour,S.A. Rahim Rezaee,Reza Farid,Akram Ghantous,Houshang Rafatpanah,Mahdi Tarhini,Mohamad-Mehdi Kooshyar,Hiba El Hajj,Fadwa Berry,Mohamad Mortada,Roudaina Nasser,Abbas Shirdel,Zeina Dassouki,Mohamad Ezzedine,Hossein Rahimi,Ardeshir Ghavamzadeh,Olivier Hermine,Mahmoud Mahmoudi,Ali Bazarbachi +18 more
TL;DR: The observed shift from a Treg/Th2 phenotype before treatment toward a Th1 phenotype after treatment with arsenic/IFN/zidovudine may play an important role in restoring an immuno-competent micro-environment, which enhances the eradication of ATL cells and the prevention of opportunistic infections.
Journal ArticleDOI
HTLV-1-host interactions on the development of adult T cell leukemia/lymphoma: virus and host gene expressions
Hanieh Tarokhian,Hossein Rahimi,Arman Mosavat,Abbas Shirdel,Houshang Rafatpanah,Mohammad Mehdi Akbarin,Alireza Bari,Samaneh Ramezani,Seyed Abdolrahim Rezaee +8 more
TL;DR: It is demonstrated that HTLV-1-PVL and HBZ and host AKT1 and Rad 51 are novel candidates for molecular targeting therapy of ATLL, however, high level of RORγt may inhibit Th1 response and complicated in ATLL progressions.
Journal ArticleDOI
Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome.
Abolghasem Allahyari,Mohsen Seddigh-Shamsi,Mahmoud Mahmoudi,Saeid Amel Jamehdar,Mahnaz Amini,Mahnaz Mozdourian,Zahra Javidarabshahi,Saeed Eslami Hasan Abadi,Shahram Amini,Alireza Sedaghat,Maryam Emadzadeh,Mohammad Moeini Nodeh,Hossein Rahimi,Alireza Bari,Zahra Mozaheb,Mostafa Kamandi,Sajad Ataei Azimi,Mojtaba Abrishami,Arezoo Akbarian,Parisa Ataei,Negin Allahyari,Sepideh Hasanzadeh,Neda Saeedian +22 more
TL;DR: Early administration of the convalescent plasma could successfully contribute to the treatment of severe COVID-19 patients with mild or moderate ARDS at risk of progressing to critical state.
Journal ArticleDOI
Assessment of HTLV-1 proviral load, LAT, BIM, c-FOS and RAD51 gene expression in adult T cell leukemia/lymphoma
Samaneh Ramezani,Abbas Shirdel,Houshang Rafatpanah,Mohammad Mehdi Akbarin,Hanieh Tarokhian,Hossein Rahimi,Alireza Bari,Hamid Reza Jahantigh,Seyed Abdolrahim Rezaee +8 more
TL;DR: This finding showed that TCR signaling pathway mainly provides the growth factors for transformed cells and the overexpression of RAD51 which has been induced in HTLV-1 infected cells as a consequence of virus replication is not able to overcome the DNA damage toward cell transformation.